Zinplava Approval History
- FDA approved: Yes (First approved October 21st, 2016)
- Brand name: Zinplava
- Generic name: bezlotoxumab
- Dosage form: Injection
- Company: Merck & Co., Inc.
- Treatment for: Prevention of Clostridium Difficile Infection Recurrence
Zinplava (bezlotoxumab) is a selective, fully-human, monoclonal antibody that binds to Clostridium difficile toxin B, indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older.
Zinplava is administered as a single dose intravenous infusion over 60 minutes during antibacterial drug treatment for CDI.
In clinical trials, heart failure was reported more commonly in Zinplava-treated patients with a history of congestive heart failure, and it recommended that patients with a history of CHF should only receive Zinplava when the benefit outweighs the risk. Common side effects include nausea, fever, and headache.
Development History and FDA Approval Process for Zinplava
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.